文献速递前列腺癌泌尿系感染

前列腺癌诊断中的感染风险与活检相关并发症:近期文献综述

Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-12-05

本综述遵循PRISMA指南系统检索2014至2025年文献,最终纳入78项研究,分析前列腺穿刺活检的感染并发症、预防策略及技术革新。结果显示经会阴穿刺感染率持续低于1%,而经直肠穿刺脓毒症发生率为0.5%至9.4%,靶向预防和影像引导技术可降低并发症并提高检出率。

要点

  • 经直肠穿刺脓毒症发生率0.5%至9.4%,发热性尿路感染0.3%至4.9%。
  • 经会阴穿刺感染率持续低于1%,可规避直肠菌群。
  • 直肠培养靶向预防、联合抗生素及直肠清洁可显著减少感染。

核心结论

  • 现代证据支持向经会阴穿刺联合靶向或多药预防转变,以降低感染风险。
  • 影像引导与机器人辅助技术提高诊断准确性和安全性,但在资源有限环境中仍受限。
  • 经直肠穿刺在无法进行经会阴穿刺时仍有应用价值,但需调整感染预防策略。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索PubMed和PubMed Central 2014至2025年文献。
  • 纳入标准为原始研究且样本量≥2例患者,重点关注感染并发症、抗生素预防和现代创新。
  • 从639条记录中筛选出78项符合纳入标准的研究,采用主题综合法分类。

主要发现

  • 经直肠穿刺后脓毒症发生率为0.5%至9.4%,发热性尿路感染为0.3%至4.9%,主要由多重耐药菌和增加采样密度驱动。
  • 经会阴穿刺避免直肠菌群,感染率持续报告低于1%。
  • 基于直肠培养的靶向预防、联合抗生素方案(如氟喹诺酮联合磷霉素或头孢曲松)及直肠清洁等辅助措施显著减少活检后感染。
  • MRI-超声融合、机器人辅助和PSMA PET/CT引导技术将癌症检出率提高至71.8%,同时保持并发症率低于5%。
  • 新兴的非抗生素经会阴方案和先进麻醉技术进一步提高了安全性和患者耐受性。

关键数值与推荐

  • 经直肠穿刺脓毒症发生率0.5%至9.4%,发热性尿路感染0.3%至4.9%。
  • 经会阴穿刺感染率持续低于1%。
  • 影像引导技术癌症检出率高达71.8%,并发症率低于5%。

临床怎么用

  • 优先选择经会阴穿刺以降低感染风险,尤其在资源允许时。
  • 采用基于直肠培养的靶向预防或联合抗生素方案,并辅以直肠清洁。
  • 在资源有限地区,经直肠穿刺仍可使用,但需强化感染预防策略。

局限性

  • 影像引导和机器人辅助技术在资源受限环境中应用有限。
  • 需要未来大规模试验和成本效益分析以优化全球活检方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer is the second most commonly diagnosed cancer worldwide. Prostate biopsy, essential for definitive diagnosis, has evolved significantly with new technologies and techniques. Transrectal ultrasound-guided biopsy (TRUS-Bx) has been the gold standard but carries substantial infectious risks due to rectal mucosal penetration. Rising antibiotic resistance, emerging safety protocols, and novel imaging-guided methods have driven a shift toward safer alternatives. METHODS: Following PRISMA guidelines, we systematically searched PubMed and PubMed Central for studies published between 2014 and 2025 on prostate puncture complications. Eligible articles included original studies with ≥2 patients, emphasizing infectious complications, antibiotic prophylaxis, and modern innovations. From 639 records screened, 78 met inclusion criteria. Thematic synthesis was used to classify findings into complication types, prophylaxis approaches, and technological advancements. RESULTS: Infectious complications after TRUS-Bx ranged from 0.5 to 9.4% for sepsis and 0.3 to 4.9% for febrile urinary tract infections, largely driven by multidrug-resistant organisms and increased sampling density. Transperineal biopsy (TP-Bx), bypassing rectal flora, consistently reported infection rates <1%. Targeted prophylaxis based on rectal cultures, combination antibiotic regimens (e.g., fluoroquinolone with fosfomycin or ceftriaxone), and adjunct measures such as rectal cleansing significantly reduced post-biopsy infections. Technological innovations such as MRI-ultrasound fusion, robotic-assisted approaches, and PSMA PET/CT-guided techniques improved cancer detection rates (up to 71.8%) while maintaining low complication rates ( < 5%). Emerging non-antibiotic TP protocols and advanced anesthetic techniques further enhanced safety and patient tolerance. CONCLUSIONS: Modern evidence supports a paradigm shift toward TP-Bx combined with targeted or multidrug prophylaxis to mitigate infectious risks. Imaging-guided and robotic-assisted techniques enhance diagnostic accuracy and safety but remain limited in resource-constrained settings. TRUS-Bx retains utility where TP access is unavailable; however, adapting infection prevention strategies is critical. Future large-scale trials and cost-effectiveness analyses are needed to optimize biopsy protocols globally.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Nikolaevich PV, Samuel AO, Fayazovich UM, et al. Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures. Prostate Cancer Prostatic Dis. 2025. PMID: 41350942. doi:10.1038/s41391-025-01061-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。